Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM/SRM and HR-MRM/PRM

Proteomics

Volumn 16, Issue 15-16, 2016, Pages 2106-2117

  Nakamura, Kenji ^a   Hirayama Kurogi, Mio ^a,b   Ito, Shingo ^a,b   Kuno, Takuya ^a,c   Yoneyama, Toshihiro ^d   Obuchi, Wataru ^d   Terasaki, Tetsuya ^d   Ohtsuki, Sumio ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

Biomedicine; CYP; Microsomes; SWATH MS; Transporter; UGT

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOCHROME P450 4A11; CYTOCHROME P450 REDUCTASE; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 6; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 3;

ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HIGH RESOLUTION MULTIPLE REACTION MONITORING; HUMAN; INTESTINE CELL; ISOTOPE LABELING; KIDNEY MICROSOME; LIMIT OF QUANTITATION; LIVER MICROSOME; MALE; MULTIPLE REACTION MONITORING; PARALLEL REACTION MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SELECTED REACTION MONITORING; TANDEM MASS SPECTROMETRY;

EID: 84983239184     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201500433     Document Type: Article

References (36)

1. Maeda, K., Sugiyama, Y., Transporter biology in drug approval: regulatory aspects. Mol. Aspects Med. 2013, 34, 711–718.
2. Gorboulev, V., Schurmann, A., Vallon, V., Kipp, H. et al., Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012, 61, 187–196.
3. Zhang, Y., Benet, L. Z., The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 2001, 40, 159–168.
4. International Transporter, C, Giacomini, K. M., Huang, S. M., Tweedie, D. J. et al., Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010, 9, 215–236.
5. Knights, K. M., Rowland, A., Miners, J. O., Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br. J. Clin. Pharmacol. 2013, 76, 587–602.
6. Asha, S., Vidyavathi, M., Role of human liver microsomes in in vitro metabolism of drugs-a review. Appl. Biochem. Biotechnol. 2010, 160, 1699–1722.
7. Bleasby, K., Castle, J. C., Roberts, C. J., Cheng, C. et al., Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006, 36, 963–988.
8. Congiu, M., Mashford, M. L., Slavin, J. L., Desmond, P. V., UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab. Dispos. 2002, 30, 129–134.
9. Rodriguez-Antona, C., Donato, M. T., Pareja, E., Gomez-Lechon, M. J., Castell, J. V., Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch. Biochem. Biophys. 2001, 393, 308–315.
10. Ohtsuki, S., Schaefer, O., Kawakami, H., Inoue, T. et al., Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 2012, 40, 83–92.
11. Ohtsuki, S., Uchida, Y., Kubo, Y., Terasaki, T., Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J. Pharm. Sci. 2011, 100, 3547–3559.
12. Fallon, J. K., Neubert, H., Hyland, R., Goosen, T. C., Smith, P. C., Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J. Proteome Res. 2013, 12, 4402–4413.
13. Harbourt, D. E., Fallon, J. K., Ito, S., Baba, T. et al., Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal. Chem. 2012, 84, 98–105.
14. Heikkinen, A. T., Friedlein, A., Matondo, M., Hatley, O. J. et al., Quantitative ADME proteomics—CYP and UGT enzymes in the Beagle dog liver and intestine. Pharm. Res. 2015, 32, 74–90.
15. Harwood, M. D., Achour, B., Russell, M. R., Carlson, G. L. et al., Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique. J. Pharm. Biomed. Anal. 2015, 110, 27–33.
16. Gillet, L. C., Navarro, P., Tate, S., Rost, H. et al., Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteomics 2012, 11, O111 016717.
17. Liu, Y., Huttenhain, R., Collins, B., Aebersold, R., Mass spectrometric protein maps for biomarker discovery and clinical research. Expert. Rev. Mol. Diagn. 2013, 13, 811–825.
18. Liu, Y., Huttenhain, R., Surinova, S., Gillet, L. C. et al., Quantitative measurements of N-linked glycoproteins in human plasma by SWATH-MS. Proteomics 2013, 13, 1247–1256.
19. Shawahna, R., Uchida, Y., Decleves, X., Ohtsuki, S. et al., Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 2011, 8, 1332–1341.
20. Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C. et al., Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors. J. Neurochem. 2011, 117, 333–345.
21. Uchida, Y., Tachikawa, M., Obuchi, W., Hoshi, Y. et al., A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS 2013, 10, 21.
22. Masuda, T., Tomita, M., Ishihama, Y., Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis. J. Proteome Res. 2008, 7, 731–740.
23. Kamiie, J., Ohtsuki, S., Iwase, R., Ohmine, K. et al., Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res. 2008, 25, 1469–1483.
24. Margaillan, G., Rouleau, M., Fallon, J. K., Caron, P. et al., Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab. Dispos. 2015, 43, 611–619.
25. Margaillan, G., Rouleau, M., Klein, K., Fallon, J. K. et al., Multiplexed targeted quantitative proteomics predicts hepatic glucuronidation potential. Drug Metab. Dispos. 2015, 43, 1331–1335.
26. Uchida, Y., Kamiie, J., Ohtsuki, S., Terasaki, T., Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm. Res. 2007, 24, 2281–2296.
27. Ohno, S., Nakajin, S., Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 2009, 37, 32–40.
28. Wang, Y. H., Trucksis, M., McElwee, J. J., Wong, P. H. et al., UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin. Pharmacol. Ther. 2012, 92, 96–102.
29. Schwienbacher, C., Sabbioni, S., Campi, M., Veronese, A. et al., Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Proc. Natl. Acad. Sci. USA 1998, 95, 3873–3878.
30. Chu, S. H., Feng, D. F., Ma, Y. B., Zhang, H. et al., Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J. Transl. Med. 2011, 9, 156.
31. Yamamoto, T., Izumi-Yamamoto, K., Iizuka, Y., Shirota, M. et al., A novel link between Slc22a18 and fat accumulation revealed by a mutation in the spontaneously hypertensive rat. Biochem. Biophys. Res. Commun. 2013, 440, 521–526.
32. Reece, M., Prawitt, D., Landers, J., Kast, C. et al., Functional characterization of ORCTL2—an organic cation transporter expressed in the renal proximal tubules. FEBS Lett. 1998, 433, 245–250.
33. Kazantzis, M., Stahl, A., Fatty acid transport proteins, implications in physiology and disease. Biochim. Biophys. Acta. 2012, 1821, 852–857.
34. Falcon, A., Doege, H., Fluitt, A., Tsang, B. et al., FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am. J. Physiol. Endocrinol. Metab. 2010, 299, E384–E393.
35. Mandell, K. J., Parkos, C. A., The JAM family of proteins. Adv. Drug. Deliv. Rev. 2005, 57, 857–867.
36. Patel, R. M., Myers, L. S., Kurundkar, A. R., Maheshwari, A. et al., Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am. J. Pathol. 2012, 180, 626–635.